TOPIC CALL 1 Q and A_Ph II.pdf

PDF 48 KB Posted

Attached to
FY2022-2026 DTRA Chemical / Biological Technologies Broad Agency Announcement
Solicitation number
HDTRA122S0002
Issued by

View the file

Other files

File Type Posted
TOPIC CALL 7 Q and A_Ph I.pdf PDF
TOPIC CALL 7.pdf PDF
ATTACHMENT 7 - Pre-award Survey of Prospective Contractor Accounting System Checklist_REVISED August 2025.pdf PDF
HDTRA122S0002_BAA_REVISED August 2025.pdf PDF
ATTACHMENT 6 - Reps and Certs_REVISED August 2025.pdf PDF
TOPIC CALL 6 Q and A_Ph I.pdf PDF
TOPIC CALL 6.pdf PDF
TOPIC CALL 4 Q and A_Ph II.pdf PDF
TOPIC CALL 5 Q and A_Ph II.pdf PDF
TOPIC CALL 5 Q and A_Ph I.pdf PDF
TOPIC CALL 4 Q and A_Ph I.pdf PDF
TOPIC CALL 5.pdf PDF
TOPIC CALL 4.pdf PDF
ATTACHMENT 4 - Supplemental Volume Cover Sheet_Rev April 2024.pdf PDF
HDTRA122S0002_BAA_REVISED April 2024.pdf PDF
ATTACHMENT 6 - Reps and Certs_REVISED April 2024.pdf PDF
TOPIC CALL 3 Q and A.pdf PDF
TOPIC CALL 3 ROM Template.xlsx XLSX spreadsheet
TOPIC CALL 3 SUBMISSION AND EVALUATION INFORMATION.pdf PDF
ATTACHMENT 6 - Reps and Certs_REVISED SEPTEMBER 2023.pdf PDF
TOPIC CALL 3.pdf PDF
TOPIC CALL 2 Q and A_Ph II.pdf PDF
TOPIC CALL 2 Q and A _Ph I.pdf PDF
TOPIC CALL 2.pdf PDF
HDTRA122S0002_BAA.pdf PDF
ATTACHMENT 1 TRL Definitions.pdf PDF
ATTACHMENT 4 - Supplemental Volume Cover Sheet.pdf PDF
ATTACHMENT 7 - SF1408.pdf PDF
TOPIC CALL 1.pdf PDF
ATTACHMENT 2 - SOW Template.pdf PDF
ATTACHMENT 6 - Reps and Certs.pdf PDF
ATTACHMENT 5 - Cost Proposal Template.xlsx XLSX spreadsheet
ATTACHMENT 3 - Data Rights Assertions List.docx DOCX document
Show all 33

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file
Try for free Login

Text version

The file's text, extracted by GovTribe without its formatting.

Questions Answers Q1: Should additional scope be incorporated into the proposed program to investigate the potential of the platform to target viral pathogens?

A1: The offeror should submit what they deem appropriate for the submission of the Phase II proposal.

Q2: Is this intended to be a request for Offeror to discuss the scientific potential in the technical proposal, without the addition of scope proposed?

A2: The offeror should submit discussion on the broad applicability of the platform.

Q3: Can the Base Period be e.g. 3.5 or 4 years or does each period have to be 12 months?

A3: The offeror should submit what they deem appropriate for the submission of the Phase II proposal.

Q4: Can Option 1 overlap with the Base Period? A4: The offeror should submit what they deem appropriate for the submission of the Phase II proposal.

Q5: Is it allowable to have two types of co-infections? Or are we restricted to one type of co-infection?

A5: The offeror is not restricted to one type of co-infection. The offeror should determine the most appropriate co-infection for the platform.

Q6: Is it correct that this project would not require studies leading to the submission of an IND to FDA at the end of the project period?

A6: This does not require submission of an IND to the FDA.

Q7: Is the intent to develop a co-infection model with two agents simultaneously administered?

A7: The offeror is not restricted to one type of co-infection. The offeror should determine the most appropriate co-infection for the platform.

Q8: Can you verify the timeline suggested is acceptable? A8: The offeror should submit a timeline that they deem appropriate for the submission of the Phase II proposal.

Q9: Can we increase the budget? A9: The offeror should submit a budget that they deem appropriate for the submission of the Phase II proposal.

Q10: Can we have a discussion with the DTRA technical team to ensure a comprehensive understanding of what they are lookin for?

A10: At this time the DTRA team is not having individual meetings with those selected to submit to Phase II.

Sheet1

File details come from the government source that posted it. Updated .